Background
According to clinical guidelines, Chlamydia trachomatis lymphogranuloma venereum (LGV), unlike non-LGV cases, should be treated with 21-day doxycycline 100 mg twice daily. However, LGV typing is rarely performed in routine care, due to limited availability and turnaround time, so most cases are empirically managed as non-LGV. The aim of the study was to estimate the proportion of LGV strains among attendees of two STIs clinics in Milan, Italy, and, in real-world practice, to preliminary compare infection clearance at test-of-cure (TOC) by empiric regimen.
Methods
We conducted a prospective observational study of individuals positive for C. trachomatis DNA, with a TOC performed within three months after completing the therapy empirically prescribed at the first visit. C. trachomatis DNA screening was performed with Allplex™ STI Essential Assay (Seegene, South Korea) while LGV typing was obtained with Genital Ulcer Real-Time PCR kit (Vircell, Spain). Demographic and clinical data were collected.
Results
From Nov 2024 to May 2025, 46 individuals with C. trachomatis infection were included, mostly males (93.5%), with a median age of 33 (IQR 29, 37) years. PrEP users and PLWH represented 78.3% and 8.7% of the population, respectively. C. trachomatis LGV DNA was detected in 13.0% of patients. Among the 46 individuals, 80.4% had anal lesions and concomitant infections were observed: ten (21.7%) N. gonorrhoeae coinfections, one (2.2%) H. ducreyi, one (2.2%) M. genitalium. Most patients (89.1%) received a 7-day doxycycline course, either alone or combined with azithromycin/ceftriaxone. Two patients suspected of LGV were treated with 21-day doxycycline, two patients with ceftriaxone + azithromycin, and one individual did not take any antibiotic. At the TOC, individuals with LGV strains, who received 7-day (three individuals) or 21-day (two individuals) doxycycline, cleared C. trachomatis LGV infection; the remaining LGV individual with C. trachomatis positive sample at TOC had received ceftriaxone + azithromycin.
Conclusions
In this study, C. trachomatis LGV strains accounted for 13% of chlamydia cases. At TOC, individuals with LGV strains treated with doxycycline (either 7 or 21 days) achieved clearance, while the only persistence of C. trachomatis DNA positivity occurred after ceftriaxone + azithromycin. These hypothesis-generating preliminary data suggest that empiric 7-day doxycycline may clear some LGV strains infections, but larger comparative studies are required.
Table or Figure